AAV8 vector expressing IL24 efficiently suppresses tumor growth mediated by specific mechanisms in MLL/AF4-positive ALL model mice

Blood

Volumn 119, Issue 1, 2012, Pages 64-71

  Tamai, Hayato ^a   Miyake, Koichi ^a   Yamaguchi, Hiroki ^a   Takatori, Miyuki ^a   Dan, Kazuo ^a   Inokuchi, Koiti ^a   Shimada, Takashi ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALCYCLIN; CASPASE 3; CASPASE 8; INTERLEUKIN 24; MIXED LINEAGE LEUKEMIA PROTEIN; PARVOVIRUS VECTOR; PROTEIN; PROTEIN MEIS1; PROTEIN P53; TRANSCRIPTION FACTOR HOXA9; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACETYLATION; ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC GENE THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CANCER MODEL; CONTROLLED STUDY; CULTURE MEDIUM; DOWN REGULATION; DRUG MECHANISM; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOPATHOLOGY; LEUKEMIA CELL LINE; MALE; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SYSTEMIC THERAPY; TUMOR VASCULARIZATION; UPREGULATION; VIRAL GENE DELIVERY SYSTEM;

EID: 84855571972     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-05-354050     Document Type: Article

References (47)

1. Harper DP, Aplan PD. Chromosomal rearrangements leading to MLL gene fusions: clinical and biological aspects. Cancer Res. 2008;68(24): 10024-10027.
2. Pui CH, Gaynon PS, Boyett JM, et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet. 2002;359(9321):1909- 1915.
3. Hu Z, Li XM, Jorgensen ML, Slayton WB. MLL/ AF-4 leukemic cells recruit newblood vessels but do not incorporate into capillaries in culture or in a NOD/SCID xenograft model. Leukemia. 2009; 23(5):990-993.
4. Tamai H, Miyake K, Yamaguchi H, et al. Resistance of MLL-AFF1-positive acute lymphoblastic leukemia to tumor necrosis factor-alpha is mediated by S100A6 upregulation. Blood Cancer J. 2011;1:e38.
5. Fernandez-Fernandez MR, Rutherford TJ, Fersht AR. Members of the S100 family bind p53 in two distinct ways. Protein Sci. 2008;17(10): 1663-1670.
6. Mueller A, Schäfer BW, Ferrari S, et al. The calcium- binding protein S100A2 interacts with p53 and modulates its transcriptional activity. J Biol Chem. 2005;280(32):29186-29193. (Pubitemid 41161370)
7. Słomnicki ŁP, Nawrot B, Leśniak W. S100A6 binds p53 and affects its activity. Int J Biochem Cell Biol. 2009;41(4):784-790.
8. Grigorian M, Andresen S, Tulchinsky E, et al. Tumor suppressor p53 protein is a new target for the metastasis-associated Mts1/S100A4 protein: functional consequences of their interaction. J Biol Chem. 2001;276(25):22699- 22708.
9. Fernandez-Fernandez MR, Veprintsev DB, Fersht AR. Proteins of the S100 family regulate the oligomerization of p53 tumor suppressor. Proc Natl Acad Sci U S A. 2005;102(13):4735- 4740.
10. Lin J, Blake M, Tang C, et al. Inhibition of p53 transcriptional activity by the S100B calcium-binding protein. J Biol Chem. 2001;276(37): 35037-35041.
11. Scotto C, Delphin C, Deloulme JC, Baudier J. Concerted regulation of wild-type p53 nuclear accumulation and activation by S100B and calcium- dependent protein kinase C. Mol Cell Biol. 1999;19(10):7168-7180. (Pubitemid 29441897)
12. Calvo KR, Sykes DB, Pasillas MP, Kamps MP. Nup98-HoxA9 immortalizes myeloid progenitors, enforces expression of Hoxa9, Hoxa7 and Meis1, and alters cytokine-specific responses in a manner similar to that induced by retroviral co-expression of Hoxa9 and Meis1. Oncogene. 2002; 21(27):4247-4256. (Pubitemid 34753831)
13. Kroon E, Thorsteinsdottir U, Mayotte N, Nakamura T, Sauvageau G. NUP98-HOXA9 expression in hemopoietic stem cells induces chronic and acute myeloid leukemias in mice. EMBO J. 2001;20(3): 350-361. (Pubitemid 32126971)
14. Faber J, Krivtsov AV, Stubbs MC, et al. HOXA9 is required for survival in human MLL-rearrangedacute leukemias. Blood. 2009;113(11):2375- 2385.
15. Nakamura T, Largaespada DA, Shaughnessy JD Jr, Jenkins NA, Copeland NG. Cooperative activation of Hoxa and Pbx1-related genes in murine myeloid leukaemias. Nat Genet. 1996;12(2):149- 153.
16. Sauvageau G, Thorsteinsdottir U, Eaves CJ, et al. Overexpression of HOXB4 in hematopoietic cells causes the selective expansion of more primitive populations in vitro and in vivo. Genes Dev. 1995; 9(14):1753-1765.
17. Thorsteinsdottir U, Mamo A, Kroon E, et al. Overexpression of the myeloid leukemia-associated Hoxa9 gene in bone marrow cells induces stem cell expansion. Blood. 2002;99(1):121-129.
18. Thorsteinsdottir U, Kroon E, Jerome L, Blasi F, Sauvageau G. Defining roles for HOX and MEIS1 genes in induction of acute myeloid leukemia. Mol Cell Biol. 2001;21(1):224-234.
19. Daga A, Podesta M, Capra MC, Piaggio G, Frassoni F, Corte G. The retroviral transduction of HOXC4 into human CD34(+) cells induces an in vitro expansion of clonogenic and early progenitors. Exp Hematol. 2000;28(5):569-574. (Pubitemid 30254458)
20. Jiang H, Lin JJ, Su ZZ, Goldstein NI, Fisher PB. Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogene. 1995; 11(12):2477-2486. (Pubitemid 26023815)
21. Ekmekcioglu S, Ellerhorst J, Mhashilkar AM, et al. Down-regulated melanoma differentiation associated gene (mda-7) expression in human melanomas. Int J Cancer. 2001;94(1):54-59. (Pubitemid 32801752)
22. Huang EY, Madireddi MT, Gopalkrishnan RV, et al. Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties. Oncogene. 2001;20(48):7051-7063. (Pubitemid 33052197)
23. Ellerhorst JA, Prieto VG, Ekmekcioglu S, et al. Loss of MDA-7 expression with progression of melanoma. J Clin Oncol. 2002;20(4):1069-1074. (Pubitemid 34141852)
24. Lebedeva IV, Su ZZ, Chang Y, Kitada S, Reed JC, Fisher PB. The cancer growth suppressing gene mda-7 induces apoptosis selectively in human melanoma cells. Oncogene. 2002;21(5):708-718. (Pubitemid 34146283)
25. Fisher PB, Gopalkrishnan RV, Chada S, et al. mda-7/IL-24, a novel cancer selective apoptosis inducing cytokine gene: from the laboratory into the clinic. Cancer Biol Ther. 2003;2(4 suppl 1): S23-S37.
26. Lebedeva IV, Sauane M, Gopalkrishnan RV, et al. mda-7/IL-24: exploiting cancer's Achilles' heel. Mol Ther. 2005;11(1):4-18. (Pubitemid 40011994)
27. Tong AW, Nemunaitis J, Su D, et al. Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. Mol Ther. 2005;11(1):160-172. (Pubitemid 40012010)
28. Qian W, Liu J, Tong Y, et al. Enhanced antitumor activity by a selective conditionally replicating adenovirus combining with MDA-7/interleukin-24 for B-lymphoblastic leukemia via induction of apoptosis. Leukemia. 2008;22(2):361-369. (Pubitemid 351250541)
29. Rahmani M, Mayo M, Dash R, et al. Melanoma differentiation associated gene-7/interleukin-24 potently induces apoptosis in human myeloid leukemia cells through a process regulated by endoplasmic reticulum stress. Mol Pharmacol. 2010; 78(6):1096-1104.
30. Caudell EG, Mumm JB, Poindexter N, et al. The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. J Immunol. 2002;168(12):6041- 6046.
31. Sarkar D, Su ZZ, Vozhilla N, Park ES, Gupta P, Fisher PB. Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice. Proc Natl Acad Sci U S A. 2005; 102(39):14034-14039. (Pubitemid 41377698)
32. Tahara I, Miyake K, Hanawa H, et al. Systemic cancer gene therapy using adeno-associated virus type 1 vector expressing MDA-7/IL24. Mol Ther. 2007;15(10):1805-1811. (Pubitemid 47434187)
33. Isotani M, Miyake K, Miyake N, Hirai Y, Shimada T. Direct comparison of four adeno-associated virus serotypes in mediating the production of antiangiogenic proteins in mouse muscle. Cancer Invest. 2011;29(5):353-359.
34. Tamai H, Miyake K, Takatori M, et al. Activated K-Ras protein accelerates human MLL/AF4-induced leukemo-lymphomogenicity in a transgenic mouse model. Leukemia. 2011;25(5):888-891.
35. Balasubramanian N, Advani SH, Zingde SM. Protein kinase C isoforms in normaland chronic myeloid leukemic neutrophils. Distinct signal for PKC alpha by immunodetection on PVDF membrane, decreased expression of PKC alpha and increased expression of PKC delta in leukemic neutrophils. Leuk Res. 1998;22(7):597-604. (Pubitemid 28327462)
36. Ringdén O, Karlsson H, Olsson R, Omazic B, Uhlin M. The allogeneic graft-versus-cancer effect. Br J Haematol. 2009;147(5):614-633.
37. Economou JS, Hoban M, Lee JD, et al. Production of tumor necrosis factor alpha and interferon gamma in interleukin-2-treated melanoma patients: correlation with clinical toxicity. Cancer Immunol Immunother. 1991;34(1):49-52.
38. Leonard JP, Sherman ML, Fisher GL, et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood. 1997;90(7):2541- 2548.
39. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003;302(5644):415-419. (Pubitemid 37296260)
40. Howe SJ, Mansour MR, Schwarzwaelder K, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest. 2008;118(9):3143-3150.
41. Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006;12(4):401-409.
42. Stein S, Ott MG, Schultze-Strasser S, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med. 2010;16(2):198-204.
43. Nichols TC, Dillow AM, Franck HW, et al. Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von Willebrand disease, and factor VII deficiency. ILAR J.2009;50(2):144-167.
44. Niemeyer GP, Herzog RW, Mount J, et al. Longterm correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. Blood. 2009;113(4):797- 806.
45. Bell P, Moscioni AD, McCarter RJ, et al. Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver. Mol Ther. 2006;14(1):34-44. (Pubitemid 43922140)
46. Schuettrumpf J, Baila S, Khazi F, Liu J, Bunte R, Arruda VR. AAV vectors do not increase the risk of tumor formation in p53 deficient models [abstract]. Mol Ther. 2007;15(suppl 1):Abstract 2.
47. Li H, Malani N, Hamilton SR, et al. Assessing the potential for AAV vector genotoxicity in a murine model. Blood. 2011;117(12):3311-3319.